Investor Presentaiton

Appendix (Financial Results for FY2022) Financial Results for FY2022 (Full Basis) Billions of yen FY2021 FY2022 Change Results Results Value % Revenue Cost of sales 560.0 555.5 (4.5) (0.8) 157.1 178.9 21.8 13.9 Gross profit 402.9 376.6 (26.3) (6.5) SG&A expenses 249.1 373.3 124.2 49.9 R&D expenses 94.9 131.9 37.0 38.9 Other operating income and expenses 1.3 51.6 50.3 Operating profit 60.2 (77.0) (137.2) Finance income and costs 22.7 29.1 6.3 Profit before taxes 83.0 (47.9) (130.9) Income tax expenses 42.4 48.8 6.4 Net profit 40.6 (96.7) (137.3) Net profit attributable to owners of the parent 56.4 (74.5) (130.9) Sumitomo Pharma © Sumitomo Pharma Co., Ltd. All Rights Reserved. 21

View entire presentation